Gelonghui, May 21丨Shijiyao Group (02005.HK) announced that the Group has obtained approval from the China National Drug Administration (“State Drug Administration”) for the production of lasagiline mesylate tablets (1mg), which is a Class 4 chemical drug and is deemed to have passed the consistency evaluation.
The Group's rasagiline mesylate has been approved by the State Drug Administration and registered as an active ingredient for use in marketed formulations. Rasagiline mesylate tablets are mainly used in the monotherapy of patients with primary Parkinson's disease and in combination with levodopa for patients with dosage fluctuations.